Cancer Landscape & Disease Burden in India
According to the Indian Council for Medical Research (ICMR), the number of cancer cases is expected to drastically increase. India is likely to have over 17.3 lakh new cases of cancer and over 8.8 lakh deaths due to the disease by 2020 [ICMR]. Therefore, it is important to find better ways to detect cancer early and improve management strategies for better treatment outcomes.
Source: Dsouza, N.D.R., Murthy, N.S. & Aras, R.Y., 2013. Projection of Burden of Cancer Mortality for India, 2011-2026. Asian Pacific Journal of Cancer Prevention, 14(7), pp.4387–4392. Available at: https://journal.waocp.org/article_27963_4ada278a9071edb596f1b32e4270cc3c.pdf [Accessed February 18, 2017].
Liquid Biopsy – A paradigm shift in cancer management
Liquid biopsy is a new technique that is increasingly being adopted for cancer diagnosis and management. Liquid biopsy can truly enable the delivery of personalized cancer therapy for every patient and every kind of cancer.
In India, Strand Life Sciences has been one of the earliest companies to introduce this revolutionary technology, in order to bring cancer care to India that is at par with the rest of the world.
What is a Liquid Biopsy?
A liquid biopsy is a test that is used to find evidence of cancer in a blood draw. Traces of tumor DNA are released into the blood from dying cancer cells and can be detected by sensitive digital technologies. This DNA can give valuable and accurate information about the presence of changes in cancer-specific genes (also known as mutations). Since the sample that we collect from the patient is a fluid (in this case blood), the technique is known as a liquid biopsy.
Strand LB Advantage
Request our brochures to find out more about the Strand LB test portfolio: